Previous studies have already substantiated that the high expression of TOP2A was markedly related to poor OS and promotes early recurrence in patients with prostate cancer 59, endometrial cancer 60, non-muscle-invasive bladder cancer 61, and adrenocortical carcinoma 62. Here, TOP2A is linked to adrenal cortex carcinoma.